Heart failure trials recruiting in Louisiana

All Heart failure trials nationally

Cities in Louisiana

Recruiting trials in Louisiana

• A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
  NCT07214376 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 85 Years · Sex: All (male and female) · Louisiana: Houma
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Bossier City, Eunice, Houma, Opelousas
• A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
  NCT07219511 · Phase: Phase 1 · Ages: 50 Years and older · Sex: All (male and female) · Louisiana: Slidell
• A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
  NCT07795814 · Phase: Phase 2 · Ages: 30 Years to 84 Years · Sex: All (male and female) · Louisiana: Houma
• A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
  NCT06024746 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Baton Rouge, West Monroe
• A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
  NCT06008197 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Baton Rouge, Hammond, West Monroe
• A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
  NCT06033950 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Baton Rouge, Hammond, West Monroe
• A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
  NCT07761117 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Bossier City, Covington, Lafayette, New Orleans
• A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
  NCT06935370 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Hammond, Shreveport
• A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
  NCT06424288 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Bossier City, Hammond, Shreveport, Slidell
• AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
  NCT06793371 · Phase: Phase 2 · Ages: 40 Years to 85 Years · Sex: All (male and female) · Louisiana: Slidell
• AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM
  NCT06378632 · Phase: Not specified · Ages: 22 Years and older · Sex: All (male and female) · Louisiana: Houma, Lafayette, New Orleans
• Alleviant ALLAY-HF Study
  NCT05685303 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Louisiana: Houma, New Orleans
• Alleviant ALLAY-HFrEF Study
  NCT06812533 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Houma, New Orleans
• Assessment of CCM in HF With Higher Ejection Fraction
  NCT05064709 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: New Orleans
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: New Orleans
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Baton Rouge
• ELEVATE-HFpEF Clinical Study
  NCT06678841 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Louisiana: Houma
• Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
  NCT01790152 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Louisiana: New Orleans
• Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF
  NCT04592445 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Louisiana: Houma
• Health Electronic Assessment of Risks and Trends Using Biometric Equipment and Technology
  NCT06753045 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female) · Louisiana: New Orleans
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
  NCT07288398 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Louisiana: New Orleans, West Monroe
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Louisiana: Baton Rouge, Covington, Hammond, Mandeville
• New Orleans Pulmonary Hypertension Biobank
  NCT03269630 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: New Orleans
• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  NCT04278404 · Phase: Not specified · Ages: 0 Years to 20 Years · Sex: All (male and female) · Louisiana: New Orleans
• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
  NCT06677060 · Phase: Phase 3 · Ages: 40 Years and older · Sex: All (male and female) · Louisiana: Alexandria, Bossier City, Shreveport
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Louisiana: Baton Rouge, Shreveport
• Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
  NCT02901184 · Phase: Phase 3 · Ages: 50 Years to 99 Years · Sex: All (male and female) · Louisiana: New Orleans
• Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
  NCT06736574 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Louisiana: New Orleans
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
  NCT06307652 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · Louisiana: Alexandria, New Orleans, Shreveport, West Monroe
• TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)
  NCT06137807 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Houma
• The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
  NCT03142152 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Louisiana: Houma, New Orleans
• Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
  NCT07221851 · Phase: Phase 3 · Ages: 2 Years to 17 Years · Sex: All (male and female) · Louisiana: New Orleans